Table 3 Sensitivity, specificity, and positive predictive value of indications for PrEP use in the past month among a sample of transgender women in the Chicago area
Past month indications for PrEP | Sensitivitya % (95% CI) | Specificityb % (95% CI) | 1-Specificityc % (95% CI) | PPVd % (95% CI) | Area under the ROC curve 95% CI |
|---|---|---|---|---|---|
Condomless vaginal/anal sex | 58.3 (27.7–84.8) | 52.4 (41.1–63.6) | 47.6 (36.9–58.5) | 15.2 (6.3–28.9) | 0.55 (0.40–0.71) |
Any HIV positive partners | 16.7 (2.1–48.4) | 93.9 (86.3–98.0) | 6.1 (2.5–14.0) | 28.6 (3.7–71.0) | 0.55 (0.44–0.67) |
STI history (ever) | 41.7 (15.2–72.3) | 75.6 (64.9–84.4) | 24.4 (16.2–35.0) | 20.0 (6.8–40.7) | 0.59 (0.43–0.74) |
Exchange sex | 41.7 (15.2–72.3) | 75.6 (64.9–84.4) | 24.4 (16.2–35.0) | 20.0 (6.8–40.7) | 0.59 (0.43–0.74) |
Combined indexe | 91.7 (61.5–99.8) | 41.5 (30.7–52.9) | 58.5 (47.5–68.8) | 18.6 (9.7–30.9) | 0.67 (0.57–0.76) |
Combined indexe + exchange sex | 91.7 (61.5–99.8) | 39.0 (28.4–50.4) | 61.0 (49.4–71.0) | 18.0 (9.4–30.0) | 0.65 (0.56–0.75) |